Opsumit, a novel dual endothelin receptor blocker marketed by Actelion Pharmaceuticals, recently gained FDA approval for treatment of PAH which can lead to lung transplantation or death. Approval for the drug was based on the results of a long-term clinical trial of 742 patients randomly assigned to Opsumit or placebo. Opsumit was determined to be effective in delaying the progression of the disease. Side effects include anemia, common cold-like symptoms, sore throat, bronchitis, headache, flu and urinary tract infections. Similar to other drugs in its class, this medication will carry a black box warning for risk of harming a developing fetus in pregnant women and includes a REMS program for dispensing to female patients. What other medications are currently used to treat pulmonary hypertension?
Click here for full article
Photo courtesy of [ddpavumba]/freedigitalphotos.net